Table 2.
Multivariate analysis for IL‐6 on clinical outcome
| Covariate | TTFT a | PFS a | ||
|---|---|---|---|---|
| HR; 95% CI | p Value | HR; 95% CI | p Value | |
| Stage | 2.706 (1.257–5.823) | 0.011 | 3.231 (1.386–7.536) | 0.007 |
| IL‐6 | 2.361 (1.081–5.160) | 0.031 | 2.171 (0.922–5.109) | 0.076 |
| 17p11q | 1.409 (0.661–3.001) | 0.374 | 1.382 (0.597–3.199) | 0.450 |
| IL‐6 | 2.543 (1.198–5.398) | 0.015 | 2.599 (1.134–5.957) | 0.024 |
| ZAP‐70 | 2.394 (0.977–5.868) | 0.056 | 2.134 (0.720–6.326) | 0.172 |
| IL‐6 | 2.885 (1.141–7.296) | 0.025 | 2.957 (0.932–9.384) | 0.066 |
| CD38 | 1.517 (0.742–3.101) | 0.254 | 1.788 (0.806–3.969) | 0.153 |
| IL‐6 | 3.091 (1.488–6.421) | 0.002 | 2.886 (1.288–6.466) | 0.010 |
Note. Effect of IL‐6 on clinical outcome was adjusted individually by each risk factor.
CI: confidence interval; HR: hazard ratio; IL‐6: interleukin 6; PFS: progression‐free survival; TTFT: shorter time to first time treatment; ZAP‐70: zeta‐associated protein‐70.
a
Number of cases = 71.